Construction of a genomic instability-derived predictive prognostic signature for non-small cell lung cancer patients
Non-small cell lung cancer (NSCLC) is the most common histologic subtype of lung cancer, accounting for over 80% of all cases[1,2]. The two common types of NSCLC are lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) [3]. Recently, monoclonal antibodies targeting the PD-1/PD-L1 axis have emerged as a primary treatment approach for advanced NSCLC [4]. However, despite the use of these antibodies, treatment outcomes remain suboptimal due to the development of drug resistance in a majority of patients. (Source: Cancer Genetics and Cytogenetics)
Source: Cancer Genetics and Cytogenetics - August 2, 2023 Category: Genetics & Stem Cells Authors: Wei Li, Huaman Wu, Juan Xu Tags: Original Article Source Type: research
Editorial Board
(Source: Cancer Genetics and Cytogenetics)
Source: Cancer Genetics and Cytogenetics - August 1, 2023 Category: Genetics & Stem Cells Source Type: research
Prognostic significance of CCND1 amplification/overexpression in smoking patients with esophageal squamous cell carcinoma
Esophageal squamous cell carcinoma (ESCC) is the main subtype of esophageal cancer, with 5-year survival rate less than 30%. In order to offer an individual therapeutic approach, it is necessary to identify novel prognostic factors to recognize high-risk patients. Given the high frequency of CCND1 abnormalities and the important biological effects of smoking in ESCC, we explored the potential relationship between CCND1 abnormalities and smoking in ESCC patients. CCND1 status was examined by fluorescence in situ hybridization and immunohistochemical staining in ESCC tissue microarrays (n=519). (Source: Cancer Genetics and Cytogenetics)
Source: Cancer Genetics and Cytogenetics - July 28, 2023 Category: Genetics & Stem Cells Authors: Dongxian Jiang, Qi Song, Fuhan Zhang, Chen Xu, Xiaojing Li, Haiying Zeng BM, Jieakesu Su, Jie Huang, Yifan Xu, Shaohua Lu, Yingyong Hou Tags: Original Article Source Type: research
Molecular subtyping and immune score system by a novel pyroptosis-based gene signature precisely predict immune infiltrating, survival and response to immune-checkpoint blockade in breast cancer
Breast cancer is currently the most frequently diagnosed cancer among women, with millions of new cases reported annually [1,2]. It is a highly heterogeneous disease with multiple molecular differences, which makes clinical treatment complicated [3]. The disease can be classified into four main molecular subtypes, including Luminal A, Luminal B, HER2-enriched, and basal-like [4]. Surgery, radiation therapy, and chemotherapy are the three main treatments for breast cancer. Targeted therapies that specifically target cancer cells, sparing healthy cells, and reducing side effects have been significant advancements in recent y...
Source: Cancer Genetics and Cytogenetics - July 21, 2023 Category: Genetics & Stem Cells Authors: Xiaomei Zeng, Xun Huang, Lingxi Yin, Hui Yu, Shiyu Wang, Lijuan Li Tags: Original Article Source Type: research
Identification of a novel stemness-related signature with appealing implications in discriminating the prognosis and therapy responses for prostate cancer
Prostate cancer is one of the most common malignancies in male adults across the world, with estimated 288,300 new cases and 34,700 deaths in 2023 [1]. For clinically localized prostate cancer, radical prostatectomy and radiotherapy are Standard of Care. Disappointingly, around 30% of prostate cancer patients will suffer from biochemical recurrence (BCR) after Standard of Care and proceed further into castration-resistant prostate cancer with a median survival of approximately 14 months (range 9 –30) [2–4]. (Source: Cancer Genetics and Cytogenetics)
Source: Cancer Genetics and Cytogenetics - July 17, 2023 Category: Genetics & Stem Cells Authors: Teng Zhang, Jun Li, Junyong Dai, Fang Yuan, Gangjun Yuan, Han Chen, Dawei Zhu, Xin Mao, Lei Qin, Nan Liu, Mingzhen Yang Source Type: research
Identification of a novel stemness-related signature with appealing implications in discriminating the prognosis and therapy responses for prostate cancer
Prostate cancer is one of the most common malignancies in male adults across the world, with estimated 288,300 new cases and 34,700 deaths in 2023 [1]. For clinically localized prostate cancer, radical prostatectomy and radiotherapy are Standard of Care. Disappointingly, around 30% of prostate cancer patients will suffer from biochemical recurrence (BCR) after Standard of Care and proceed further into castration-resistant prostate cancer with a median survival of approximately 14 months (range 9-30) [2 –4]. (Source: Cancer Genetics and Cytogenetics)
Source: Cancer Genetics and Cytogenetics - July 17, 2023 Category: Genetics & Stem Cells Authors: Teng Zhang, Jun Li, Junyong Dai, Fang Yuan, Gangjun Yuan, Han Chen, Dawei Zhu, Xin Mao, Lei Qin, Nan Liu, Mingzhen Yang Source Type: research
Rare concomitance of ETV6::RUNX1 and BCR::ABL1p210 in a child diagnosed with B-cell precursor acute lymphoblastic leukemia
ETV6::RUNX1 and BCR::ABL1 are primary events in pediatric B-cell precursor acute lymphoblastic leukemia (B-ALL), with ETV6::RUNX1 being much more frequent (20-25% vs 2-3%). Elegant studies have shown that these are founder leukemogenic events, but additional genetic alterations are needed for leukemia onset [1,2]. The presence of both ETV6::RUNX1 and BCR::ABL1 in the same patient is a very rare finding and has been previously reported in only two B-ALL cases, one pediatric and one young adult patient [3,4]. (Source: Cancer Genetics and Cytogenetics)
Source: Cancer Genetics and Cytogenetics - July 14, 2023 Category: Genetics & Stem Cells Authors: TC Barbosa, E Oliveira, CB Blunck, ALT Maciel, ACF Bastos, HFA Bouzada, ST Rouxinol, MB Mansur, ES Costa, CW Almeida, M Emerenciano Tags: Case Report Source Type: research
Myeloid/Lymphoid Neoplasm with FGFR1 Rearrangement Presenting with Polycythemia Vera and T-cell Acute Lymphoblastic Leukemia.
Myeloid/lymphoid neoplasm with fibroblast growth factor 1 rearrangements (MLN-FGFR1) represents a rare group of hematologic neoplasms, with approximately 100 cases reported to date. A 69-year-old woman with a history of polycythemia and leukocytosis, with negative molecular testing for JAK2, CALR, and MPL, presented with diffuse adenopathy. A lymph node (LN) biopsy revealed effacement by T-lymphoblasts, consistent with T-cell acute lymphoblastic lymphoma (T-ALL). A staging bone marrow (BM) biopsy demonstrated trilineage hyperplasia, which, taken together with the patient's elevated hemoglobin and low serum erythropoietin l...
Source: Cancer Genetics and Cytogenetics - July 12, 2023 Category: Genetics & Stem Cells Authors: Lisa M. Marinelli, Joshua T. Romain, William Ehman, Veronica Ortega, Gopalrao Velagaleti, Thomas F. Gibbons, Ashley Nazario-Toole, Allen R. Holmes Source Type: research
Cryptic KMT2A/MLLT10 fusion detected by next-generation sequencing in a case of pediatric acute megakaryoblastic leukemia
KMT2A rearrangement is a common chromosomal aberration that occurs in about 10% of acute leukemias [1]. KMT2A (11q23.3; formerly MLL) gene rearrangements are found in both pediatric and adult acute leukemias and associated with a poor or intermediate prognosis [2]. KMT2A has a number of gene fusion partners, with MLLT10 (10p12.31; formerly AF10) being the fourth most common. Although it has been documented in congenital and infant leukemia, therapy-related acute myeloid leukemia (AML), B- and T-lymphoblastic leukemia/lymphoma, and mixed-phenotype acute leukemia (MPAL), KMT2A/MLLT10 fusion is most commonly seen in pediatric...
Source: Cancer Genetics and Cytogenetics - July 11, 2023 Category: Genetics & Stem Cells Authors: Yeseul Kim, Boram Kim, Moon-Woo Seong, Dong Soon Lee, Kyung Taek Hong, Hyoung Jin Kang, Jiwon Yun, Yoon Hwan Chang Tags: Short Communication Source Type: research
Integrated exome sequencing and microarray analyses detected genetic defects and underlying pathways of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the seventh most common cancer with estimated 0.84 million new cases per year, and the fifth leading cause of cancer-related mortality with estimated 0.78 million deaths per year worldwide [1]. HCC has several known risk factors including hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, alcohol abuse, autoimmune hepatitis, diabetes mellitus, obesity, and several metabolic diseases [2,3]. These risk factors induced initial liver injury followed by progressive inflammatory milieu, a cycle of necrosis, regeneration, and accumulated genetic alterations for HCC [4]. (Source: Canc...
Source: Cancer Genetics and Cytogenetics - June 27, 2023 Category: Genetics & Stem Cells Authors: Mei Ling Chong, James Knight, Gang Peng, Weizhen Ji, Hongyan Chai, Yufei Lu, Shengming Wu, Peining Li, Qiping Hu Source Type: research
Unfolded Protein Response Signature Unveils Novel Insights into Breast Cancer Prognosis and Tumor Microenvironment
Breast cancer (BC) is responsible for almost one-third of all cancer cases in women, with an annual incidence rate that is increasing by 0.5% from 2014 to 2018 [1]. According to estimates, there will be a total of 297,790 newly diagnosed cases of breast cancer in the United States in 2023, representing approximately 31% of all newly diagnosed cancer cases in the female population [2]. BC is a highly intricate and heterogeneous disease, characterized by different molecular spectra, clinical responses to treatment, and prognoses [3]. (Source: Cancer Genetics and Cytogenetics)
Source: Cancer Genetics and Cytogenetics - June 14, 2023 Category: Genetics & Stem Cells Authors: Nanyang Zhou, Dejia Kong, Qiao Lin, Xiaojing Yang, Dan Zhou, Lihua Lou, Feixiang Huang Source Type: research
Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia
Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute lymphoblastic leukemia (Ph+ ALL), acute myeloid Leukemia (Ph+ AML), myelodysplastic syndrome (Ph+ MDS). (Source: Cancer Genetics and Cytogenetics)
Source: Cancer Genetics and Cytogenetics - May 27, 2023 Category: Genetics & Stem Cells Authors: Ajeet Kumar, Vijai Tilak, Disha Arora, Marisha, Rahul, Deepak Gautam, Akhtar Ali Source Type: research
Philadelphia chromosome-positive myelodysplastic syndrome with single lineage dysplasia
Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute lymphoblastic leukemia (Ph+ ALL), acute myeloid Leukemia (Ph+ AML), myelodysplastic syndrome (Ph+ MDS). (Source: Cancer Genetics and Cytogenetics)
Source: Cancer Genetics and Cytogenetics - May 27, 2023 Category: Genetics & Stem Cells Authors: Ajeet Kumar, Vijai Tilak, Disha Arora, Marisha, Rahul, Deepak Gautam, Akhtar Ali Source Type: research
Editorial Board
(Source: Cancer Genetics and Cytogenetics)
Source: Cancer Genetics and Cytogenetics - May 24, 2023 Category: Genetics & Stem Cells Source Type: research
Distinct mechanisms of PTEN inactivation in dogs and humans highlight convergent molecular events that drive cell division in the pathogenesis of osteosarcoma
Osteosarcoma, the most common primary tumor of bone, is very rare in humans, but is commonly observed in large and giant dogs [1]. Human and canine osteosarcoma share many driver events including mutation of the TP53 tumor suppressor gene [2,3-11], and somatic fragmentation and rearrangement of chromosome structure which leads to recurrent increases and decreases in DNA copy number [4,8]. As a result, canine osteosarcoma is considered an excellent model for studying the genomic and biochemical events that govern disease progression. (Source: Cancer Genetics and Cytogenetics)
Source: Cancer Genetics and Cytogenetics - May 20, 2023 Category: Genetics & Stem Cells Authors: Aaron L. Sarver, Lauren J. Mills, Kelly M. Makielski, Nuri A. Temiz, Jinhua Wang, Logan G. Spector, Subbaya Subramanian, Jaime F. Modiano Tags: Original Article Source Type: research
